Thu, March 17, 2011
Wed, March 16, 2011
Tue, March 15, 2011
Mon, March 14, 2011
[ Mon, Mar 14th 2011 ] - Market Wire
30 AM E.T.
Sun, March 13, 2011
Sat, March 12, 2011
Fri, March 11, 2011
[ Fri, Mar 11th 2011 ] - Market Wire
Covidien????????????????FDA??
Thu, March 10, 2011
Wed, March 9, 2011
Tue, March 8, 2011
Mon, March 7, 2011
Sat, March 5, 2011
Fri, March 4, 2011
Thu, March 3, 2011
Wed, March 2, 2011
[ Wed, Mar 02nd 2011 ] - Market Wire
BURCON AMENDS LETTER OF INTENT
Tue, March 1, 2011
Mon, February 28, 2011

Medivation Announces Fourth Quarter and Year-End 2010 Financial Results Teleconference and Webcast on March, 16 2011


//health-fitness.news-articles.net/content/2011/ .. teleconference-and-webcast-on-march-16-2011.html
Published in Health and Fitness on Wednesday, March 9th 2011 at 5:11 GMT by Market Wire   Print publication without navigation


SAN FRANCISCO, CA--(Marketwire - March 9, 2011) - Medivation, Inc. (NASDAQ: [ MDVN ]) today announced that it will host a teleconference and webcast with management to discuss fourth quarter and year-end 2010 financial results and provide a general business update on March 16, 2011, at 4:30 p.m. Eastern Time. A press release for the fourth quarter and year ended on December 31, 2010, will be released after markets close on March 16, 2011.

Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals interested in listening to the live call via webcast may do so by visiting [ http://www.medivation.com ]. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at [ www.medivation.com ].


Publication Contributing Sources